NRx Pharmaceuticals (NASDAQ:NRXP) has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife vaccine can produce effective neutralizing antibody levels against the omicron variant.
- The Company also said that many of the mutations in the omicron variant had been identified in the spike protein of the BriLife vaccine.
- This natural evolution of the BriLife vaccine suggests that the vaccine may continue to evolve to address future Variants of Concern.
- Unlike the current mRNA vaccines and attenuated virus vaccines, the BriLife vaccine is a live, viral vector vaccine in which the spike protein of the SARS-CoV-2 virus has been added to a benign virus.
- The findings were based on blood samples (sera) of patients vaccinated during the Phase 2 trial of the BriLife vaccine conducted in Israel.
- These sera indicated a mean neutralization titer (NT50) of 53 against omicron vs. a titer of 152 against the original wild-type virus and 131 against the delta variant.
- The IIBR report documents that 10 of 13 tested sera demonstrated clinically detectable levels of Omicron-neutralizing antibody.
- NRx is currently designing a Phase 2b/3 study of the BriLife vaccine as a booster against COVID-19 variants of concern, including the omicron variant. The study will start in Q1 of FY22.
- Price Action: NRXP shares are down 2.30% at $2.98 during the market session on the last check Thursday.
